Stockscreener 앱 받기
66.04
0.05%
0.03
시간 외 거래:
66.04
전일 마감가:
$66.01
열려 있는:
$66.23
하루 거래량:
1.60M
Relative Volume:
0.90
시가총액:
$13.13B
수익:
$2.59B
순이익/손실:
$256.59M
주가수익비율:
85.91
EPS:
0.7687
순현금흐름:
$212.80M
1주 성능:
-5.54%
1개월 성능:
-4.99%
6개월 성능:
-19.89%
1년 성능:
-17.02%
1일 변동 폭
$65.45
$66.23
1주일 범위
$65.35
$69.67
52주 변동 폭
$65.35
$99.56
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
BioMarin's SWOT analysis: rare disease biotech stock faces growth challenges - Investing.com
New York State Teachers Retirement System Purchases 14,281 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
BMRN vs. INCY: Which Stock Is the Better Value Option? - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Leerink Partnrs Brokers Decrease Earnings Estimates for BMRN - MarketBeat
Raymond James & Associates Lowers Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharm - GuruFocus.com
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN) - Yahoo Finance
Cantor Fitzgerald Issues Positive Estimate for BMRN Earnings - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2024 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
(BMRN) Proactive Strategies - Stock Traders Daily
Short Interest in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Expands By 5.9% - MarketBeat
William Blair Downgrades BioMarin Pharmaceutical (BMRN) - MSN
International Assets Investment Management LLC Takes $12.94 Million Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $93.67 Average PT from Brokerages - MarketBeat
Earnings call: BioMarin reports robust Q3 growth with VOXZOGO sales surge - Investing.com Canada
BioMarin stock rating downgraded to market perform after Q3 earnings beat - Investing.com Canada
BioMarin stock touches 52-week low at $67.36 amid market shifts - Investing.com India
BioMarin stock rating downgraded to market perform after Q3 earnings beat By Investing.com - Investing.com South Africa
BioMarin stock touches 52-week low at $67.36 amid market shifts By Investing.com - Investing.com South Africa
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth - Benzinga
BioMarin downgraded at William Blair following narrowing of revenue guidance - MSN
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised - Zacks Investment Research
BioMarin stock target cut, keeps neutral stance on Q3 financial results - Investing.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Earns Sector Perform Rating from Royal Bank of Canada - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Earnings Results, Misses Expectations By $0.23 EPS - MarketBeat
UBS Group Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 52-Week Low Following Weak Earnings - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) PT Lowered to $65.00 at Robert W. Baird - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Cut to Market Perform at William Blair - MarketBeat
Citi cautious on BioMarin stock as Voxzogo misses, growth outlook moderates - Investing.com
BioMarin Reports Strong Q3 Growth and Positive Outlook - TipRanks
Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
BioMarin: Q3 Earnings Snapshot - The Washington Post
BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates - MSN
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Biomarin Pharma earnings beat by $0.38, revenue topped estimates - Investing.com Nigeria
Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024 - Marketscreener.com
BioMarin Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
China Universal Asset Management Co. Ltd. Raises Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast - Benzinga
BioMarin appoints new business chief and R&D head - MSN
BioMarin Rises as It Trims Spending on Fizzling Gene Therapy - MSN
Here's Why You Should Invest in BioMarin (BMRN) Stock Now - MSN
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):